Global Leading Market Research Publisher QYResearch announces the release of its latest report “Recombinant Human Thrombin (rhThrombin) - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Recombinant Human Thrombin (rhThrombin) market, including market size, share, demand, industry development status, and forecasts for the next few years.

For surgeons, operating room teams, and hospital procurement specialists, achieving rapid, reliable topical hemostasis during surgical procedures is essential for minimizing blood loss, reducing operative time, and improving patient outcomes. Recombinant Human Thrombin (rhThrombin)—a genetically engineered, pathogen-free alternative to plasma-derived thrombin—offers consistent purity, predictable activity, and significantly reduced risk of immunogenic reactions. As surgical volumes increase and the demand for safer biologic hemostatic agents grows, rhThrombin is positioned for steady adoption across a range of surgical specialties, addressing the critical need for effective bleeding control without the safety concerns associated with animal-derived or human plasma products.

The global market for Recombinant Human Thrombin (rhThrombin) was estimated to be worth US$ 260 million in 2025 and is projected to reach US$ 343 million, growing at a CAGR of 4.1% from 2026 to 2032. In 2024, global Recombinant Human Thrombin (rhThrombin) sales reached approximately 772 thousand vials, with an average global market price of around US$ 325 per vial. Recombinant Human Thrombin (rhThrombin) is a genetically engineered form of the natural human thrombin enzyme, produced using recombinant DNA technology in non-human cell lines such as CHO or HEK293 cells. It plays a critical role in the coagulation cascade by converting fibrinogen into fibrin, facilitating blood clot formation. rhThrombin is primarily used as a topical hemostatic agent during surgical procedures to control bleeding, offering a pathogen-free alternative to plasma-derived thrombin. It provides consistent purity, reduces the risk of immunogenic reactions.

[Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)]
https://www.qyresearch.com/reports/6094631/recombinant-human-thrombin--rhthrombin

Product Segmentation and Clinical Utilization

The market is segmented by dosage strength into 5,000 IU/vial and 20,000 IU/vial formulations. The 5,000 IU/vial segment accounts for approximately 58% of total sales volume in 2024, driven by its preference in routine surgical procedures where lower dosing is sufficient for focal bleeding control. The 20,000 IU/vial segment is favored in complex surgical cases, including vascular, hepatic, and spinal procedures where larger surface areas or more extensive bleeding require higher dosing.

By application, hospitals represent the dominant end-user segment, accounting for over 85% of rhThrombin utilization. Within hospitals, usage is concentrated in surgical departments including cardiovascular, general, orthopedic, and neurologic surgery. According to QYResearch’s clinical utilization tracking data, the highest adoption rates are observed in procedures where precise topical hemostasis is critical, including liver resections, vascular anastomoses, and spinal surgeries.

Technical Advantages and Differentiation from Plasma-Derived Alternatives

rhThrombin offers several distinct advantages over traditional plasma-derived and bovine thrombin products. First, recombinant production eliminates the risk of pathogen transmission associated with human plasma-derived products. Second, the absence of bovine proteins eliminates the risk of developing antibodies against bovine thrombin and factor V, which can lead to life-threatening coagulopathies. Third, consistent manufacturing processes ensure batch-to-batch uniformity in potency and purity.

A representative case involves a major academic medical center that transitioned from bovine thrombin to rhThrombin for all spinal and vascular surgeries in Q1 2025. According to post-implementation data shared with QYResearch, the transition resulted in a 94% reduction in thrombin-related adverse event reports, with surgeons reporting comparable or superior hemostatic efficacy across all procedure types.

Regulatory Landscape and Market Access

Regulatory frameworks for recombinant biologics require comprehensive characterization of product quality, safety, and efficacy. The FDA approved rhThrombin as a topical hemostatic agent with specific labeling for use in surgical settings where control of bleeding from capillaries and small venules is required. The European Medicines Agency (EMA) has similarly approved rhThrombin with indications covering a broad range of surgical procedures.

Recent regulatory developments have focused on comparative effectiveness and safety. The FDA’s 2025 guidance on biologic hemostatic agents emphasizes the importance of demonstrating safety advantages over existing alternatives, particularly regarding immunogenicity risk. This has reinforced the value proposition of rhThrombin relative to bovine and plasma-derived products, supporting continued market penetration.

Exclusive Observation: Concentrated Market Structure and Emerging Competition

A defining characteristic of the rhThrombin market is its highly concentrated structure. Currently, Baxter dominates the global market with its branded product, while Suzhou Zelgen Biopharmaceuticals represents the primary competitor, particularly in the Asia-Pacific region. According to QYResearch’s market analysis, Baxter accounts for approximately 76% of global rhThrombin sales volume, reflecting first-mover advantages, established regulatory approvals, and extensive commercial infrastructure.

However, the market is poised for gradual evolution. Suzhou Zelgen has expanded its commercial footprint beyond China in 2025, securing regulatory approvals in several Southeast Asian markets. Additionally, QYResearch’s pipeline analysis indicates that two additional recombinant thrombin candidates are in late-stage clinical development, with potential market entry by 2028–2029. This emerging competition is expected to expand market access and potentially moderate pricing, particularly in price-sensitive markets.

Exclusive Observation: Expanding Surgical Applications

Beyond traditional surgical hemostasis, rhThrombin is finding expanded applications in minimally invasive and robotic surgery settings. As surgical techniques evolve toward smaller incisions and reduced tissue manipulation, the need for precise, targeted hemostatic agents has increased. rhThrombin’s ease of application, rapid onset of action, and favorable safety profile make it well-suited for these emerging surgical paradigms. According to QYResearch’s surgical procedure tracking data, rhThrombin utilization in minimally invasive procedures grew at a CAGR of 9.3% from 2021 to 2025, outpacing overall market growth.

Market Segmentation

The Recombinant Human Thrombin (rhThrombin) market is segmented as below:

Segment by Type:

5,000 IU/Vial

20,000 IU/Vial

Segment by Application:

Hospitals

Clinics

Others

Key Industry Participants
The market is characterized by a concentrated competitive landscape with two primary manufacturers:
Baxter, Suzhou Zelgen Biopharmaceuticals.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp